centchroman has been researched along with Adenocarcinoma, Basal Cell in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ganju, A; Gara, RK; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N; Zhao, H | 1 |
Balapure, AK; Kaushik, S; Sharma, R; Shyam, H; Singh, N | 1 |
2 other study(ies) available for centchroman and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Apoptosis; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Centchroman induces redox-dependent apoptosis and cell-cycle arrest in human endometrial cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Centchroman; Cyclin D1; Cyclin E; DNA Fragmentation; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidation-Reduction; Protein Transport | 2017 |